Billionaire Stanley Druckenmiller's 2 New Healthcare Stock Picks
Stanley Druckenmiller's Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc.
Definium Therapeutics Inc. (DFTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 0 | $0 | 0% | |
| 2. | Quantinno Capital Hoon Kim | 0 | $0 | 0% | |
| 3. | OrbiMed Advisors Samuel Isaly | 0 | $0 | 0% | |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 0 | $0 | 0% | |
| 5. | Millennium Management Israel Englander | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.17 | 2,500 | $17,925.00 | 19,851 | 2024-12-05 | Filing | |
| $5.98 | 3,500 | $20,930.00 | 17,351 | 2024-08-23 | Filing | |
| $6.12 | 500 | $3,060.00 | 565,543 | 2024-08-20 | Filing | |
| $6.31 | 500 | $3,155.00 | 565,043 | 2024-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.94 | 19,023 | $721,732.62 | 1,494,640 | 2026-09-03 | Filing | |
| $45.03 | 13,008 | $585,750.24 | 320,571 | 2026-06-25 | Filing | |
| $45.03 | 3,013 | $135,675.39 | 209,487 | 2026-06-25 | Filing | |
| $45.03 | 29,208 | $1,315,236.24 | 1,098,246 | 2026-06-25 | Filing | |
| $45.03 | 10,035 | $451,876.05 | 503,282 | 2026-06-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1 | $1 | 0% | |
| 2. | 0 | $0 | 0% |
News See All
Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S.
Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best psychedelic stocks on our list.
7 Best Psychedelic Stocks to Buy According to Analysts
In this article, we will be taking a look at the 7 Best Psychedelic Stocks to Buy According to Analysts.
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best biotech stocks on this list.
10 Best Biotech Stocks to Buy According to Analysts
In this article, we will be taking a look at the 10 Best Biotech Stocks to Buy According to Analysts.
10 Stocks Paying Off Big Time
Ten stocks kicked off the trading week with strong gains, bucking a lackluster performance on the broader market, thanks to a flurry of positive industry news that spilled over to their stocks.
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q1 2026 Earnings Call Transcript
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q1 2026 Earnings Call Transcript May 7, 2026Definium Therapeutics, Inc. misses on earnings expectations.
9 Best Psychedelic Stocks to Buy in 2026
In this article, we will discuss the 9 Best Psychedelic Stocks to Buy in 2026.
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 Earnings Call Transcript February 26, 2026Definium Therapeutics, Inc. reports earnings inline with expectations.